Clinical trials: Atherosclerotic Disease
Lipidemia, Coronary Artery Disease
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally…
- Conditions
- Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
- Trial name
- REMBRANDT (NCT06305559)
- Testing
- obicetrapib 10 mg + ezetimibe 10 mg FDC daily
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- NewAmsterdam Pharma
Hypercholesterolemia
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
A multicenter study to evaluate safety and efficacy of inclisiran in Asian patients with ASCVD or ASCVD high risk and elevated LDL-C
- Trial name
- NCT04765657
- Testing
- inclisiran sodium
- Where
- 45 sites in China, Singapore and 2 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease, Type 2 Diabetes Mellitus
Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM
This study will evaluate the efficacy and aafety of rosuvastatin/ezetimibe combination therapy vs. rosuvastatin monotherapy in atherosclerotic cardiovascular disease patients with type 2 diabetes mellitus
- Trial name
- MIRA (NCT03597412)
- Testing
- Rosuvamibe, Monorova
- Where
- South Korea
- Volunteers
- 236 people
- Sponsor
- Yuhan Corporation
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current…
- Trial name
- NCT02666664
- Testing
- ETC-1002
- Where
- 104 sites in United States, Canada and 4 more
- Volunteers
- 2,230 people
- Sponsor
- Esperion Therapeutics, Inc.
Coronary Stenosis, Acute Coronary Syndrome
Coronary Plaque Geometry and Acute Coronary Syndromes
The aim of GEOMETRY study is to investigate the correlation between coronary plaque geometric modifications and lesion vulnerability in patients with suspected coronary artery disease referred for cardiac computed tomography…
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atherosclerosis
- Trial name
- NCT03702764
- Testing
- CCTA
- Where
- Romania
- Volunteers
- 1,000 people
- Sponsor
- Cardio Med Medical Center
Mixed Hyperlipidemia
Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia
- Trial name
- RADIANCE 2 (NCT00134238)
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 51 sites in United States, Canada and 4 more
- Volunteers
- 755 people
- Sponsor
- Pfizer
Plaque, Atherosclerotic Disease
BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population
The BioImage Study is a study of the characteristics of subclinical cardiovascular disease, as measured by imaging modalities, unsupervised circulating biomarker measurements, and risk factors that predict progression to overt…
- Conditions
- Plaque, Atherosclerotic Disease, Heart Disease, Stroke
- Trial name
- NCT00738725
- Where
- 2 sites in United States
- Volunteers
- 7,687 people, healthy volunteers welcome
- Sponsor
- BG Medicine, Inc
Atherosclerotic Cardiovascular Disease
Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis
The purpose of the study is to assess the effect of BMS-823778 on reducing atherosclerotic plaque inflammation
- Trial name
- NCT01666704
- Testing
- BMS-823778
- Sponsor
- Bristol-Myers Squibb
Atherosclerotic Disease
CAPTURE Study (Polyglucosamine for Cardio & Atherosclerosis Prevention and Treatment Via Fat Uptake REduction)
This clinical investigation is intended to confirm the application of a new intended purpose and a new indication for an already certified medical device.
- Trial name
- CAPTURE (NCT06910111)
- Testing
- Polyglucosamine
- Where
- 3 sites in Italy
- Volunteers
- 240 people
- Sponsor
- Certmedica International GmbH
Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents
Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
The purpose of this study was to evaluate the implementation of inclisiran in a regional primary care setting in the UK Inclisiran, also known as KJX839, is a medication made to reduce the level of "bad" cholesterol…
- Conditions
- Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol
- Trial name
- SPIRIT (NCT04807400)
- Testing
- Inclisiran, Behavioural Support, Background lipid lowering therapy
- Where
- 17 sites in United Kingdom
- Volunteers
- 892 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with…
- Trial name
- OPTIMA (NCT07034690)
- Testing
- Educational Material, Standard of care
- Where
- United Arab Emirates
- Volunteers
- 326 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Disease
Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs
The purpose of this study is to obtain the distribution of measurements of the intima media thickness of carotid arteries in people with high cardiovascular risk.
- Trial name
- CIMT (NCT00970918)
- Testing
- Measurement of the Carotid Intima Media thickness, Blood sample testing for hs-CRP
- Where
- 19 sites in China, India and 7 more
- Volunteers
- 2,609 people
- Sponsor
- AstraZeneca
Carotid Artery Diseases, Stroke
Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH)
The purpose of this study is to determine whether morbidity and mortality for high-risk surgical patients treated with the Carotid Wallstent in conjunction with the FilterWire EX and EZ System distal protection device will be…
- Conditions
- Carotid Artery Diseases, Stroke, Cerebral Arteriosclerosis
- Trial name
- BEACH (NCT00316108)
- Testing
- WALLSTENT® Endoprosthesis™
- Where
- 50 sites in United States
- Volunteers
- 747 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
The REVEALPLAQUE Study: A pRospEctiVe, multicEnter Study to AnaLyze PLAQUE Using CCTA
This study will evaluate the level of agreement between noninvasive CCTA (coronary computed tomography angiography)-based quantification and characterization of coronary atherosclerosis and invasive IVUS (intravascular…
- Trial name
- REVEALPLAQUE (NCT05138289)
- Testing
- Total Plaque Volume
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- HeartFlow, Inc.
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
- Trial name
- MOVE-Lp(a) (NCT07157774)
- Testing
- Muvalaplin
- Where
- 804 sites in United States, Argentina and 26 more
- Volunteers
- 10,450 people
- Sponsor
- Eli Lilly and Company
Cardiovascular Risk
Precision Study of CLAiR AI Software
This multi-site precision study evaluated the performance and reproducibility of the CLAiR artificial intelligence (AI) software in identifying elevated risk of atherosclerotic cardiovascular disease (ASCVD) from retinal fundus…
- Trial name
- NCT07747233
- Testing
- CLAiR Artificial Intelligence Software
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Toku Eyes Ltd
Stroke, Intracranial Atherosclerotic Stenosis
SeQuent ® Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis
This study is aiming to evaluate the safety and efficacy of SeQuent® Please CIS in the endovascular treatment of symptomatic intracranial atherosclerotic stenosis and restenosis after interventional therapy.
- Trial name
- SPINAS (NCT06047964)
- Testing
- DCB, POBA
- Where
- 9 sites in China
- Volunteers
- 281 people
- Sponsor
- B. Braun Medical International Trading Company Ltd.
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists
The purpose of this survey is to collect information for scientific research and to better understand the role of systemic inflammation in identification, treatment and management of patients with ASCVD and CKD.
- Trial name
- FLAME-ASCVD (NCT05755373)
- Testing
- No treatment given
- Where
- India
- Volunteers
- 602 people
- Sponsor
- Novo Nordisk A/S
Atherosclerotic Cardiovascular Disease
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this…
- Trial name
- STaRT (NCT06858332)
- Testing
- Atorvastatin, Simvastatin, Rozuvastatin
- Where
- 20 sites in Russia
- Volunteers
- 2,382 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Study CKJX839B1FR01 in an In silico trial to predict the efficacy of Inclisiran therapy on major adverse cardiovascular events (MACE) and cardiovascular (CV) death in virtual patients with atherosclerotic cardiovascular disease…
- Trial name
- SIRIUS (NCT05974345)
- Testing
- Inclisiran sodium, Ezetimibe, Evolocumab
- Where
- France
- Volunteers
- 204,691 people
- Sponsor
- Novartis Pharmaceuticals